Sysmex Corporation (6869)

Name: Sysmex Corporation (6869) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-21

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing.

Cifras clave

Capitalización bursátil: JPY 1.12 trillion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 500.0B
Beneficio neto: JPY 35.5B
Margen bruto: 51.1%
Margen neto: 7.1%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Ingresos totales	JPY 500.0B	JPY 508.6B	JPY 461.5B	JPY 410.5B	—
Beneficio bruto	JPY 255.7B	JPY 272.0B	JPY 242.5B	JPY 216.1B	—
Ingresos operativos (EBIT)	JPY 63.4B	JPY 90.8B	JPY 80.6B	JPY 76.0B	—
Ingresos netos	JPY 35.5B	JPY 53.7B	JPY 49.6B	JPY 45.8B	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 6869. /companies/us/6869

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.